News 2017
Miami-Dade's Quest to Make Everyone Knowledgeable About PrEP
Kira Villamizar, Manager, Public Health Services, Florida Department of Health, Miami-Dade County
Imagine discovering the promise of pre-exposure prophylaxis (PrEP) for the first time and determining that it can lower your risk of becoming HIV positive. You get up the nerve to go to your primary care physician and ask him or her if you are a candidate for the treatment, and your doctor either dismisses your question or, even worse, has no idea what PrEP is.
Read more: Miami-Dade's Quest to Make Everyone Knowledgeable About PrEP
In This Issue
This week, we share the results of research performed in New York and Washington, D.C., to find out whether offering financial assistance to people living with HIV and AIDS could help incentivize them to enter care and take their meds so they can suppress their viral load.
Could a Monetary Perk Help Keep HIV Patients on Their Meds?
Wafaa El-Sadr, M.D., MPH, MPA, Professor of Epidemiology and Medicine, Mailman School of Public Health, Columbia University
There are mixed results from a new study on the use of monetary rewards to help boost the odds that HIV-infected patients will enter care, and take their meds as directed.
Read more: Could a Monetary Perk Help Keep HIV Patients on Their Meds?
Quantity Over Quality? Minorities Shown To Get An Excess Of Ineffective Care
Sometimes more isn't better
Minority patients face a double whammy: Not only are they more likely to miss out on effective medical treatments than white patients, but, according to a new study, they're also more likely to receive an abundance of ineffective services.
Read more: Quantity Over Quality? Minorities Shown To Get An Excess Of Ineffective Care
Scientific Meeting Advances Efforts to Cure HCV Infection in the Ryan White HIV/AIDS Care Act Program
Corinna Dan, R.N., M.P.H., Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
Earlier this year, I had the opportunity to join colleagues at the Health Resources and Services Administration's (HRSA) HIV/AIDS Bureau (HAB) and an invited group of clinical experts for a scientific consultation on expanding hepatitis C virus (HCV) treatment among people living with HIV.